172 related articles for article (PubMed ID: 37647853)
1. How I treat transplant-eligible patients with myelofibrosis.
Kröger N; Wolschke C; Gagelmann N
Blood; 2023 Nov; 142(20):1683-1696. PubMed ID: 37647853
[TBL] [Abstract][Full Text] [Related]
2. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.
Tiribelli M; Palandri F; Sant'Antonio E; Breccia M; Bonifacio M
Bone Marrow Transplant; 2020 Apr; 55(4):708-716. PubMed ID: 31534197
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
El Fakih R; Popat U
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.
Keyzner A; Han S; Shapiro S; Moshier E; Schorr E; Petersen B; Najfeld V; Kremyanskaya M; Isola L; Hoffman R; Mascarenhas J
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2180-2186. PubMed ID: 27596130
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem-cell transplantation for myelofibrosis.
Lavi N; Rowe JM; Zuckerman T
Curr Opin Hematol; 2017 Nov; 24(6):475-480. PubMed ID: 28832353
[TBL] [Abstract][Full Text] [Related]
6. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.
Khanlari M; Wang X; Loghavi S; Wang SA; Li S; Thakral B; Bueso-Ramos CE; Yin CC; Kanagal-Shamanna R; Khoury JD; Patel KP; Popat UR; Medeiros LJ; Konoplev S
Ann Diagn Pathol; 2022 Feb; 56():151860. PubMed ID: 34823075
[TBL] [Abstract][Full Text] [Related]
7. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
[TBL] [Abstract][Full Text] [Related]
8. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
Morsia E; Gangat N
Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
[No Abstract] [Full Text] [Related]
9. 2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.
Ali H; Bacigalupo A
Am J Hematol; 2021 Nov; 96(11):1532-1538. PubMed ID: 34536293
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.
Kekre N; Ho VT
Am J Hematol; 2016 Jan; 91(1):123-30. PubMed ID: 26453238
[TBL] [Abstract][Full Text] [Related]
11. Stem cell transplant for the treatment of myelofibrosis.
Mannelli L; Guglielmelli P; Vannucchi AM
Expert Rev Hematol; 2020 Apr; 13(4):363-374. PubMed ID: 32077336
[No Abstract] [Full Text] [Related]
12. Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021.
Bacigalupo A; Innocenti I; Rossi E; Sora F; Galli E; Autore F; Metafuni E; Chiusolo P; Giammarco S; Laurenti L; Benintende G; Sica S; De Stefano V
Front Immunol; 2021; 12():637512. PubMed ID: 34017327
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
14. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Viswabandya A; Devlin R; Gupta V
Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?
Babushok D; Hexner E
Curr Opin Hematol; 2014 Mar; 21(2):114-22. PubMed ID: 24378706
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
Gupta V; Hari P; Hoffman R
Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
[TBL] [Abstract][Full Text] [Related]
18. Transplantation algorithm for myelofibrosis in 2022 and beyond.
Hernández-Boluda JC; Czerw T
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101369. PubMed ID: 36333063
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
Gupta V; Gotlib J; Radich JP; Kröger NM; Rondelli D; Verstovsek S; Deeg HJ
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1274-81. PubMed ID: 24680977
[TBL] [Abstract][Full Text] [Related]
20. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.
Polverelli N; Farina M; D'Adda M; Damiani E; Grazioli L; Leoni A; Malagola M; Bernardi S; Russo D
Cells; 2022 Feb; 11(3):. PubMed ID: 35159362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
